Xu Jiao-Ya, Li Zhong-Ping, Zhang Li, Ji Guang
Jiao-Ya Xu, Zhong-Ping Li, Li Zhang, Guang Ji, Institute of Digestive Diseases, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China.
World J Gastroenterol. 2014 Oct 7;20(37):13493-500. doi: 10.3748/wjg.v20.i37.13493.
Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic syndrome and is one of the most prevalent liver disorders worldwide. NAFLD can gradually progress to liver inflammation, fibrosis, cirrhosis and even hepatocellular carcinoma. However, the pathogenesis of NAFLD is complex, and no efficient pharmaceutic treatments have yet been established for NAFLD. Accumulating data have shown that the farnesoid X receptor (FXR) plays important roles not only in bile acid metabolism, but also in lipid and carbohydrate homeostasis, inflammatory responses, among others. In this review, we aim to highlight the role of FXR in the pathogenesis and treatment of NAFLD.
非酒精性脂肪性肝病（NAFLD）是代谢综合征的肝脏表现，也是全球最常见的肝脏疾病之一。NAFLD可逐渐发展为肝脏炎症、纤维化、肝硬化甚至肝细胞癌。然而，NAFLD的发病机制复杂，目前尚未建立有效的药物治疗方法。越来越多的数据表明，法尼醇X受体（FXR）不仅在胆汁酸代谢中起重要作用，而且在脂质和碳水化合物稳态、炎症反应等方面也发挥重要作用。在本综述中，我们旨在强调FXR在NAFLD发病机制和治疗中的作用。
